Researchers randomized patients with advanced neuroendocrine tumors 2:1 to receive either cabozantinib or placebo.

PURPOSE: Molecular radiotherapy is a treatment modality that is highly suitable for targeting micrometastases and [177Lu]Lu-DOTATATE is currently being explored as a potential novel treatment ...

6 Lutetium Lu 177 Dotatate: Comprehensive Guidelines for Dosing, Administration, and Safety Lutetium Lu 177 dotatate is a radiopharmaceutical therapy approved for the treatment of SSTR-positive ...

Novartis’s leading radioconjugates—Pluvicto (lu-177 vipivotide tetraxetan) and Lutathera (lu-177 dotatate)— are both ...

While Lutathera was the first of its radionuclides to reach the market, Novartis’ flagship therapy is Pluvicto (lutetium lu177 vipivotide tetraxetan), which was approved by the FDA for PSMA ...

Dr. Jonathan R. Strosberg, discussed results of the CABINET trial evaluating Cabometyx versus placebo in advanced ...

AAA's leading investigational therapeutic candidate, lutetium Lu 177 dotatate (Lutathera), is a novel MNM compound that AAA is currently developing for the treatment of neuro-endocrine tumors.

Lutetium Lu 177 vipivotide tetraxetan is under clinical development by Advanced Accelerator Applications and currently in Phase III for Hormone-Sensitive Prostate Cancer. According to GlobalData, ...

Lutetium Lu 177 vipivotide tetraxetan is under clinical development by Advanced Accelerator Applications and currently in Phase III for Metastatic Prostate Cancer. According to GlobalData, Phase III ...

for prostate cancer and Novartis's Lutathera (lutetium Lu 177 dotatate) for neuroendocrine tumours (NETs), which delivers beta radiation. Ratio's Trillium platform uses an albumin carrier to ...

During 2024, the radiopharmaceutical Pluvicto achieved blockbuster status, while sales of the breast cancer drug Kisqali grew 46 percent compared to 2023.